Merck (NYSE: MRK) enters Clinical Trial Collaboration And Supply Agreement With OncoSec Medical Incorporated (NASDAQ: ONCS)

July 8, 2021

OncoSec Medical Incorporated (NASDAQ: ONCS) jumped 21.86% after entering a Clinical Trial Collaboration and Supply Agreement with Merck (NYSE: MRK) to study the combination of its DNA plasmid interleukin-12 TAVO with Merck’s KEYTRUDA (pembrolizumab) in a randomized third phase clinical study, KEYNOTE-C87. Merck and OncoSec to conduct KEYNOTE-C87 study The clinical trial will assess overall patient survival for patients treated with OncoSec’s TAVO in combination with Merck’s KEYTRUDA compared to…